A delicate balance: Tweaking IL-2 immunotherapy

Nature Medicine

Volumn 18, Issue 2, 2012, Pages 208-209

  Ferrara, James L M ^a   Malek, Thomas ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CELLULAR IMMUNITY; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HEPATITIS C; HUMAN; IMMUNOLOGY; REGULATORY T LYMPHOCYTE; VASCULITIS;

GRAFT VS HOST DISEASE; HEPATITIS C; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY; VASCULITIS;

EID: 84859170354     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0212-208     Document Type: Article

References (11)

1. Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055-2066 (2011).
2. Saadoun, D. et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067-2077 (2011).
3. Atkins, M.B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
4. + regulatory T cells. Blood 118, 2342-2350 (2011).
5. Willenbacher, W. et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.Br. J. Haematol. 112, 820-823 (2001).
6. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775-787 (2008).
7. Malek, T.R. & Castro, I. Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 33, 153-165 (2010).
8. Rosenberg, S.A. & Lotze, M.T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 4, 681-709 (1986).
9. Yu, A., Zhu, L., Altman, N.H. & Malek, T.R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30, 204-217 (2009).
10. Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
11. reg cells with IL-2-mAb complexes: Induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751-760 (2009).